Cargando…

Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression

BACKGROUND. To investigate post-treatment changes in serum testosterone in low- and intermediate-risk prostate cancer patients treated with hypofractionated passively scattered proton radiotherapy. MATERIAL AND METHODS. Between April 2008 and October 2011, 228 patients with low- and intermediate-ris...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kil, Whoon Jong, Nichols, Romaine C., Hoppe, Bradford S., Morris, Christopher G., Marcus, Robert B., Mendenhall, William, Mendenhall, Nancy P., Li, Zuofeng, Costa, Joseph A., Williams, Christopher R., Henderson, Randal H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613975/ https://www.ncbi.nlm.nih.gov/pubmed/23477360 http://dx.doi.org/10.3109/0284186X.2013.767983

Ejemplares similares

Does Race Influence Health-related Quality of Life and Toxicity Following Proton Therapy for Prostate Cancer?
por: Bryant, Curtis, et al.
Publicado: (2016)

Erectile Function, Incontinence, and Other Quality of Life Outcomes Following Proton Therapy for Prostate Cancer in Men 60 Years Old and Younger
por: Hoppe, Bradford S, et al.
Publicado: (2012)

Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: Results of two prospective trials
por: Henderson, Randal H., et al.
Publicado: (2013)

Postoperative or Salvage Proton Radiotherapy for Prostate Cancer After Radical Prostatectomy
por: Kharod, Shivam M., et al.
Publicado: (2021)

Prognostic factors of radiation dermatitis following passive-scattering proton therapy for breast cancer
por: Liang, Xiaoying, et al.
Publicado: (2018)

Proton therapy in the management of non-Hodgkin lymphoma
por: Sachsman, Suzanne, et al.
Publicado: (2015)

Insurance Approval for Definitive Proton Therapy for Prostate Cancer
por: Mendenhall, William M., et al.
Publicado: (2021)

Image-Guided Hypofractionated Proton Therapy in Early-Stage Non–Small Cell Lung Cancer: A Phase 2 Study
por: Kharod, Shivam M., et al.
Publicado: (2020)

Passively Scattered Proton Therapy for Nonmelanoma Skin Cancer with Clinical Perineural Invasion
por: Bryant, Curtis M., et al.
Publicado: (2021)

Dosimetric characterization of whole brain radiotherapy of pediatric patients using modulated proton beams
por: Jin, Hosang, et al.
Publicado: (2011)

Ultra-Hypofractionated Proton Therapy in Localized Prostate Cancer: Passive Scattering versus Intensity-Modulated Proton Therapy
por: Borowicz, Dorota Maria, et al.
Publicado: (2021)

Comparative Effectiveness of Proton Therapy versus Photon Radiotherapy in Adolescents and Young Adults for Classical Hodgkin Lymphoma
por: Bates, James E., et al.
Publicado: (2021)

Irradiating Residual Disease to 30 Gy with Proton Therapy in Pediatric Mediastinal Hodgkin Lymphoma
por: Hoppe, Bradford S., et al.
Publicado: (2020)

Consensus Statement on Proton Therapy for Prostate Cancer
por: Bryant, Curtis M., et al.
Publicado: (2021)

An Analytical Model of Leakage Neutron Equivalent Dose for Passively-Scattered Proton Radiotherapy and Validation with Measurements
por: Schneider, Christopher, et al.
Publicado: (2015)

Pulmonary Function after Proton Therapy for Hodgkin Lymphoma
por: O'steen, Lillie, et al.
Publicado: (2019)

Optimizing neoadjuvant radiotherapy for resectable and borderline resectable pancreatic cancer using protons
por: Nichols, Romaine Charles, et al.
Publicado: (2019)

A Beam-Angle-Selection Method to Improve Inter-Fraction Motion Robustness for Lung Tumor Irradiation With Passive Proton Scattering
por: Zhang, Yawei, et al.
Publicado: (2020)

A comprehensive dosimetric study of Monte Carlo and pencil‐beam algorithms on intensity‐modulated proton therapy for breast cancer
por: Liang, Xiaoying, et al.
Publicado: (2018)

Intrafractional Displacement of Cardiac Substructures Among Patients With Mediastinal Lymphoma or Lung Cancer
por: Guzhva, Lidia, et al.
Publicado: (2019)

Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
por: Kim, Hun Jung, et al.
Publicado: (2016)

Normal tissue complication probability models for prospectively scored late rectal and urinary morbidity after proton therapy of prostate cancer
por: Pedersen, Jesper, et al.
Publicado: (2021)

Clinical and radiobiological consideration of cyclical hypofractionated radiation therapy also known as QUAD Shot for neglected skin cancer disfiguring the face of a non-compliant patient who was refusing surgery and protracted radiation therapy: case report
por: Kil, Whoon Jong, et al.
Publicado: (2019)

Dosimetric consequences of image guidance techniques on robust optimized intensity-modulated proton therapy for treatment of breast Cancer
por: Liang, Xiaoying, et al.
Publicado: (2020)

Hypofractionated Radiotherapy in Intermediate-Risk Prostate Cancer Patients: Long-Term Results
por: Valeriani, Maurizio, et al.
Publicado: (2022)

Proton Therapy With Concurrent Chemotherapy for Thoracic Esophageal Cancer: Toxicity, Disease Control, and Survival Outcomes
por: Rutenberg, Michael S., et al.
Publicado: (2022)

Evaluation of the dosimetric effect of scattered protons in clinical practice in passive scattering proton therapy
por: Kim, Chankyu, et al.
Publicado: (2021)

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
por: Anwar, Mekhail, et al.
Publicado: (2016)

Hypofractionated Radiotherapy in Localized, Low–Intermediate-Risk Prostate Cancer: Current and Future Prospectives
por: Lo Greco, Maria Chiara, et al.
Publicado: (2023)

What men want: Results from a national survey on decision making for prostate cancer treatment and research participation
por: Mendenhall, Nancy P., et al.
Publicado: (2021)

Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer
por: Crane, Christopher H.
Publicado: (2016)

Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer
por: Soni, Abhishek, et al.
Publicado: (2022)

Protons Safely Allow Coverage of High-Risk Nodes for Patients with Regionally Advanced Non-Small-Cell Lung Cancer
por: Nichols, R. C., et al.
Publicado: (2011)

5-Years Analysis of Effectivity and Toxicity of Ultra-Hypofractionated Proton Radiotherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer—A Retrospective Analysis
por: Kubeš, Jiri, et al.
Publicado: (2023)

Hypofractionated radiotherapy for breast cancer acceleration of the START A treatment regime: intermediate tolerance and efficacy
por: Janssen, Stefan, et al.
Publicado: (2014)

Cost-effectiveness analysis of ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy for intermediate- to high-risk localized prostate cancer
por: He, Jiaoxue, et al.
Publicado: (2023)

Use of diverging apertures to minimize the edge scatter in passive scattering proton therapy
por: Zhao, Tianyu, et al.
Publicado: (2015)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

The Role of Hypofractionation in Proton Therapy
por: Santos, Alexandre, et al.
Publicado: (2022)

Hypofractionated Proton Boost Combined with External Beam Radiotherapy for Treatment of Localized Prostate Cancer
por: Johansson, Silvia, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_svmimel0vd9o80s53nlojt7f93